Novartis will acquire majority control of Alcon, Inc., entering an all-share direct merger with Alcon for the remaining the 23% stake it did not previously own. The move completes Novartis’ April 2008 agreement with Nestlé S.A. that led to Novartis taking a 77% in Alcon. “The addition of Alcon will strategically strengthen our healthcare portfolio and our position in eye care, a sector with dynamic growth due to the increasing patient needs of an aging population,” said Dr. Daniel Vasella, ch...